Liver Cancer Treatment Market is Expected to Reach $3.03 bn by 2027
The Liver Cancer Treatment Market was valued at US$ 736.42 million in the year 2019 and is estimated to reach US$ 3.03 billion by 2027, at a CAGR of 19.33%.
Liver cancer is the 6th most common types of cancer affecting the global population with over 840,000 new cases reported in 2018 alone. It also accounts for around 9% of total cancer-related mortalities, globally. The South-East countries, low- & middle-income countries are more vulnerable to acquire liver cancer than the US & European nations. Liver cancer incidence is higher around the age of 70. However, in the Asian countries, the disease can affect individuals as early as at the age of 40.
Generally, liver cancer is categorized into primary and secondary types. The primary type of liver cancer originates in the liver itself while the second type is the one which affects the liver through metastasis of the cancer cells originated elsewhere in the body. Hepatocellular carcinoma is the major type accounting for 70-90% of the cases which can arise from an infection or cirrhosis of the liver. Followed by which the intrahepatic cholangiocarcinoma that originates in the bile duct is affecting around 10-20% of the cases, globally. Rest of the liver cancer types is rare in nature.
Request for sample @ https://www.optimainsights.org/sample-request/7-liver-cancer-treatment-market
Men are more prone to liver cancer than women with major risk factors such as alcoholism, overweight, weak immune system; exposure to aflatoxins, activation of oncogenes, gender, etc. are the major causative of liver cancer. The disease is mostly asymptomatic till the advanced stages. Nevertheless, it can be diagnosed using CT, MRI, ultrasound, blood tests and biopsy. Primarily, the treatment can involve but not limited to surgical removal of the tumour, radiation therapy, chemotherapy, immunotherapy, targeted therapy, etc. Yet, the 5-year survival rate is about 31%, if treated early and 11% 5-year survival rate for metastatic liver cancer that had spread to lymph nodes.
The major share of the liver cancer treatment landscape is dominated by the North American region, especially the US accounting for more than 42% of the market share, with more awareness of the disease, availability of therapeutics, early diagnosis, healthcare infrastructure, etc. Further, an increase in the geriatric population, presence of major players and product launches is also expected to drive the market. Followed by the US are Japan and the South East Asian Region with more dominance in the treatment landscape.
Partial Surgical Removal of the infected area is one of the primary treatment procedures followed for hepatocellular carcinoma (HCC) with resection of the cirrhotic area that increases the mortality rates. Nexavar, Stivarga, Opdivo are primary and secondary-line of treatments prescribed for treating HCC. Besides, combinatorial therapy is also prescribed to ease the tumour resistance and to maintain the quality of life. There are no efficacious drugs for treating liver cancer and is one of the major challenges. Many small molecules are under development with monoclonal antibodies, RNAi technology and oncolytic viruses have gained significant attention in recent times.
This study provides the latest insights on the industry trends, products & pipeline along with country, regional and global revenue forecast till the year 2027. The analysis of the market is segmented into Cancer Type (Hepatocellular carcinoma, Cholangio carcinoma, hemangiosarcoma, Hepatoblatoma, Hepatic adenoma and Focal nodular hyperplasia); Therapy type (Ablative therapy, Chemotherapy, Radiation Therapy, Immunotherapy, and Targeted Therapy) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
The major players in the market include Bayer, Bristol-Myers Squibb, Celsion Corp, Eisai, F. Hoffman La Roche, ImClone Systems Inc, Jennerex Biotherapeutics Inc, Merck, Ono Pharmaceutical, Onyx Pharmaceuticals, Pfizer and many more…
• Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
• Provides a Comparative Analysis of Key Marketed and Pipeline Products.
• Provides Key Information on Players involved.
• Provides a Complete Overview of Market Segments and the Regional Outlook.
• Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Liver Cancer Treatment Market, 2015 to 2018
- Forecast of the Liver Cancer Treatment Market Growth till the year 2027
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Liver Cancer Treatment Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/7-liver-cancer-treatment-market
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)